Your Health, We Care
On February 15, 2024, the FDA approved tepotinib for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) carrying a skipping mutation in exon 14 of mesenchymal epithelial transition factor (MET).
The VISION study aims to evaluate the efficacy and safety of tepotinib as a monotherapy for advanced or metastatic NSCLC patients carrying METex14 skipping mutations.
